⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Ammonia-Lowering Agents
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-08-01 — Ammonia Metabolism in the Aging Liver: Emerging Mechanistic Insights.: Narrative review reframes age-related decline of hepatic urea-cycle and glutamine-synthesis capacity as converting ammonia into a bioactive stress signal driving mitochondrial injury, senescence, proteostasis failure, and liver–brain/liver–muscle/liver–gut deterioration, positioning ammonia-lowering agents (e.g. lactulose, rifaximin, LOLA, sodium phenylbutyrate/benzoate) as candidate healthspan interventions rather than only overt hepatic encephalopathy drugs — conceptual synthesis, no new outcome data. [mechanism-plausible] (novelty: 3)
Open questions
Related
Contributing findings
Ammonia Metabolism in the Aging Liver: Emerging Mechanistic Insights.
01-aug-2026
novelty 3
per-area 3
strengthens